Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
#330 most reported symptom for this vaccine
Blood product transfusion has been reported 46 times in association with Meningococcal Conjugate (Menactra) vaccination in VAERS. This represents 0.1% of all 36,149 reports for this vaccine.
Among these reports, 2 mentioned death (4.35%) and 43 involved hospitalization (93.5%).
Blood product transfusion is the #330 most frequently reported symptom for Meningococcal Conjugate (Menactra) out of 1843 total symptoms.
Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.
Seeing 46 reports of Blood product transfusion after Meningococcal Conjugate (Menactra) vaccination may seem alarming, but context is critical.
The mortality rate of 4.35% warrants monitoring, though VAERS deaths represent temporal associations, not confirmed causal links.
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.